Introduction {#s1}
============

Abnormal DNA methylation in the gene promoter region is a well-recognized epigenetic hallmark in the premalignant and malignant stages of cancers, and it has been observed in different kinds of genes, such as tumor suppressor genes and DNA repair genes ([@B34]; [@B12]; [@B14]; [@B18]; [@B64]; [@B13]). Methylation of the CpG sites in promoter regions can lead to gene dysfunction or inactivation, causing tumor progression ([@B40]; [@B46]). Several studies have reported that promoter methylation status of multiple genes is associated with cervical precancerous lesions (CPL) and cervical cancer (CC) development, such as CDH13, CDKN2B, TIM3, and RASSF1A ([@B11]; [@B36]; [@B28]). Methylation has been detected at cervical precancerous stages, and methylated DNA is a relatively stable target and allows for flexibility of assay development, suggesting that methylation markers may have value in cervical diseases screening ([@B56]; [@B51]). DNA methylation of promoter regions is associated with the cervical disease, but very few studies have been reported for gene promoter methylation related to antiviral innate immunity pathways, moreover, the research evaluating DNA methylation and epidemiologic factors for CPL and CC is very limited in Chinese women.

CC is one of the most common malignancies in women, with an estimated 530,000 new cases and 275,000 deaths worldwide per year ([@B62]). Approximately 90% of the deaths from CC occurred in low- and middle-income countries during 2015. The mortality of CC has significantly decreased in China, but a younger age trend and a substantial increase in CC incidence have been seen in some regions ([@B49]; [@B9]). The incidence and mortality of cervical disease vary widely among different populations, geographic areas and time periods in China ([@B29]). The incidence and mortality rates of CC could be reduced through effective screening, early prevention and diagnosis ([@B43]). High-risk human papillomavirus (hrHPV) is the cause of CPL and CC ([@B37]), and hrHPV prevalence is well correlated with the risk of diseases, particularly in middle-age women ([@B42]; [@B33]; [@B6]). The squamous intraepithelial lesions (SILs) of the cervix are referred to as CPL, which can be divided into low-grade SIL (LSIL or cervical intraepithelial neoplasia 1, CIN1) and high-grade SIL (HSIL or CIN2/3) histologically. The progression from LSIL through HSIL and eventually to invasive cancer lasts up to 10--30 years ([@B58]; [@B27]). The periods of CPL are generally chronic and reversible; therefore, various methods can be adopted to prevent carcinogenesis, and the stage of CPL might be affected by many genetic or environmental factors ([@B2]).

Viral infection of the host can trigger innate immune responses, and previous studies have revealed that cyclic GMP-AMP synthase (*cGAS*)/*STING* and *RIG-I*/*MAVS* pathways play important roles in host innate immunity against HPV-induced precursor lesions and invasive cancer of the uterine cervix ([@B24]; [@B26]; [@B61]). *cGAS*, also known as MB21D1 or C6orf150, is identified as a general cytosolic DNA sensor, which can detect intracellular DNA and catalyze the synthesis of second messenger cyclic-GMP-AMP (cGAMP) from ATP and GTP ([@B52]). Then synthesized cGAMP binds to and activates the adaptor protein *STING* (stimulator of interferon genes) to induce the phosphorylation of downstream factors, including TANK binding kinase 1 (*TBK1*) and interferon regulatory factor 3 (*IRF3*), thereby triggering type-I interferon (IFN) production ([@B59]; [@B26]). Type I IFNs are critical for antiviral autoimmune responses. The *RIG-I*/*MAVS* pathway can also mediate IFN production in response to cytosolic double-stranded RNA or single-stranded RNA containing 5'-triphosphate (5'-ppp) ([@B25]; [@B22]). RNA polymerase III (Pol-III) has been suggested to function as a potential DNA sensor that can identify and convert cytosolic DNA into 5'-triphosphate (5'-ppp) RNA ([@B22]; [@B44]; [@B10]), which can be detected by *RIG-I* sensor and lead to the mitochondrial assembly of mitochondrial antiviral-signaling (*MAVS*) complexes. Then, *MAVS* binds to tumor necrosis factor receptor-associated factor 3 (*TRAF3*) and recruits TBK1/IKKε kinases that activate NF-κB and direct the phosphorylation of constitutively expressed IRF3 to induce IFN-β ([@B16]; [@B41]; [@B21]; [@B32]).

In this study, we investigated the promoter methylation status of *cGAS*, *MAVS*, and *TRAF3* in CPL and CC, and we further explored the association between potential biological interactions and the risk of CPL and CC in the Southern Chinese population.

Materials and Methods {#s2}
=====================

Study Participants {#s2_1}
------------------

A total of 205 Southern Chinese women were recruited in our study, including 97 healthy women in the control group and 108 patients with CPL and CC. The mean age was 45.50 years, ranging from 20 to 65 years. The classifications of the groups were according to the ThinPrep cytologic test (TCT) with the Bethesda system for reporting cervical cytology (TBS 2001) and cervical biopsies were confirmed by two pathologists. The women in the control group were negative for CPL or CC without other diseases of uterus or cervix. The CPL group (n = 75) was women with SILs, including 38 with LSILs and 37 with HSILs. There were 33 patients in the CC group.

Epidemiological data were obtained from the face-to-face questionnaire of each study subject; these questionnaires were conducted by qualified investigators and a doctor to ensure the accuracy and authenticity of the information. In addition, peripheral venous blood and cervical epithelial exfoliated cells were also collected from each participant. The blood sample was gathered with EDTA vacuum collection tubes and maintained at 4 degrees; then, blood samples were transported to our laboratory for DNA and RNA extraction. Cervical epithelial exfoliated cells were collected by cytobrush (QIAGEN, Valencia, CA) and preserved in denaturation buffer. ThinPrep 2000 (Hologic Inc.) and SurePath liquid-based Pap test (BD, USA) were used for the TCT. HPV DNA from cervical samples was extracted from the commercial magnetic beads kit (Chemagen, PerkinElmer, Waltham, MA), which was performed in the clinical standard laboratory of BGI (Beijing Genomics Institute, Shenzhen, China). Both hrHPV (types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68) and low-risk HPV (lrHPV, types 6 and 11) were detected with MassARRAY (Sequenom, Sandiego, CA) based on the matrix-assisted laser desorption/ionization time of flight (MALDI-TOF) mass spectrometry (MS).

Methylation Status Detection {#s2_2}
----------------------------

The promoter region is approximately 2000-bp length upstream of the gene transcription start site, and the reference promoter sequences for the human *cGAS, MAVS*, and *TRAF3* genes are obtained from the UCSC Gene Sorter (<http://www.genome.ucsc.edu/cgi-bin/hgNear>). The methylation status is described as percentage of methylated CpGs of the possible CpG methylation sites, which is detected by the bisulfite sequencing PCR (BSP) technique. The BSP is the most widely used method to give information about the methylation profile of every single CpG site in a given sequence. We use MethPrimer (<http://www.urogene.org/methprimer/index1.html>) to carry out the bisulfite transformation of the target sequences and design primers ([@B30]), which is based on key CpG island prediction in the promoter regions of genes *cGAS*/*MAVS*/*TRAF3* ([**Figure 1**](#f1){ref-type="fig"}).

![The target sequences\' bisulfite transformation and design primers in the promoter regions of genes cGAS/MAVS/TRAF3.](fgene-10-01123-g001){#f1}

Blood DNA was extracted using the QIAamp DNA Mini Kit (QIAGEN, 51104), and the bisulfite-treated DNA was purified using the Wizard DNA Clean-up System (Promega, A7290) after DNA denaturation and bisulfite conversion. The DNA was PCR-amplified by using the EpiTaq HS Kit (TaKaRa, R110A) in a 20-µl reaction volume with the designed primers ([**Table S1**](#SM1){ref-type="supplementary-material"}). The PCR conditions consisted of an initial incubation for 3 min at 98°C, followed by 40 cycles of 10 s at 98°C, 30 s at 55°C, and 30 s at 72°C, and finally 10 min at 74°C. The PCR product was sequenced by IGE (Guangzhou IGE Biotechnology, LTD., China), and the sequencing results were analyzed using Chromas software. There were 9, 10, and 5 CpG sites detected in the promoter region of the *cGAS*, *MAVS*, and *TRAF3* genes, respectively. The methylation status was dependent on the peak height of cytosine (C) and thymine (T) signals according to the following formula:
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Statistical Analyses {#s2_3}
--------------------

The demographic and experimental data were obtained and recorded, and the database was established by Epidata software. Data analyses were performed with SPSS software (version 24.0, Inc., Chicago, USA). Differences among the groups of control, CPL, and CC were assessed by analysis of variance (ANOVA), Dunnett's t-test, chi-squared test, and Mann-Whitney U test. Correlation analysis was conducted using the logistic regression model, which was calculated by estimating the odds ratios (ORs) and 95% confidence intervals (95% CIs) after adjusting for potential covariates. Potential two-factor interaction was evaluated on an additive scale with a 95% CI by calculating the following three measures: synergy index (S), attributable proportion due to interaction (AP), and relative excess risk due to interaction (RERI) ([@B50]; [@B1]). If there were no biological interactions, then the 95% CI of S is over 1, and RERI and AP are cross 0 ([@B3]; [@B1]). Multifactor dimensionality reduction software 1.0.0 (MDR 1.0.0) was used to explore the multifactor interactions, and the best model was determined by the testing balanced accuracy (TBA) and cross-validation consistency (CVC) indexes. All *p* values below 0.05 were considered statistically significant.

Result {#s3}
======

Demographic Characteristics and Relevant Factors Analysis {#s3_1}
---------------------------------------------------------

Demographic characteristics and analysis of relevant factors are shown in [**Table 1**](#T1){ref-type="table"}. The patients in the CC group were older than in the control group, and the number of pregnancies was higher in the CC group than in the control group (*p* \<0.05). The positive rates of hrHPV in both the CPL (74.67%) and CC (82.35%) groups were significantly higher than in the control group (53.61%). However, there were no significant differences in other factors among the groups (*P* \> 0.05).

###### 

Demographic characteristics in control, CPL, and CC.

  Variables                  Control N = 97    CPL N = 75        CC N = 33         F/χ^2^   *p* value
  -------------------------- ----------------- ----------------- ----------------- -------- -------------
  Age                        44.24 ± 7.14^b^   44.52 ± 7.35^c^   51.61 ± 9.88^b^   12.212   **\<0.001**
  BMI                        22.02 ± 3.31      22.06 ± 2.55      22.43 ± 3.05      0.241    0.786
  Age at menarche            15.21 ± 1.74      15.47 ± 2.64      14.32 ± 1.54      3.047    0.050
  Age at first intercourse   22.47 ± 3.97      22.63 ± 3.18      22.63 ± 2.91      0.048    0.953
  Age at primiparity         23.81 ± 3.40      23.88 ± 3.58      23.06 ± 5.36      0.551    0.577
  Number of pregnancies      3.02 ± 1.28^b^    3.25 ± 1.39 ^c^   3.72 ± 1.63 ^b^   3.141    **0.045**
  Number of births           2.38 ± 0.93       2.67 ± 1.78       2.69 ± 1.47       1.725    0.181
  Number of abortions        0.64 ± 0.88       0.59 ± 0.95       1.03 ± 1.36       2.423    0.091
  HrHPV infection                                                                           
  Negative                   45 (46.39)        19 (25.33)        3 (17.65)         10.784   **0.005**
  Positive                   52 (53.61)^b^     56 (74.67)^b^     14 (82.35)^b^              
  Unavailable                0                 0                 16                         
  Passive smoking                                                                           
  Negative                   38 (39.20)        24 (32.00)        12 (41.40)        1.24     0.538
  Positive                   59 (60.80)        51 (68.00)        17 (58.60)                 
  Unavailable                0                 0                 4                          
  Physical exercise                                                                         
  Negative                   84 (86.60)        67 (89.30)        25 (75.76)        3.562    0.169
  Positive                   13 (13.40)        8 (10.70)         8 (24.24)                  

Data is shown means ± standard deviation for continuous variable, and the number of samples is shown for categorical variable. P value is based on ANOVA or Chi-square test. Bold values indicate the statistically significant p value (p \< 0.05). The same letter of b/c indicates that the significant differences compared with the control group. CPL, cervical precancerous lesions; CC, cervical cancer; HrHPV, high-risk HPV; BMI, body mass index, kg/m^2^. HrHPV positive is including HPV negative and low-risk HPV positive.

Gene Promoter Methylation Status in Control, CPL, and CC {#s3_2}
--------------------------------------------------------

The methylation rate of a single CpG site and the methylation levels of gene promoter regions are presented in [**Table 2**](#T2){ref-type="table"}. The methylation status of the single CpG site was as follows: the methylation level of the *cGAS*, *MAVS*, and *TRAF3* genes and the methylation rates of the C1-C8 CpG sites of *cGAS*, M1-M9 CpG sites of *MAVS*, and T1-T4 CpG sites of *TRAF3* were higher in the CPL group than in the control group (*P* \< 0.05); C1 and C2 in *cGAS*, M4 and M10 in *MAVS*, as well as T3 in *TRAF3* were higher in the CC group than in the control group (*P* \< 0.05). The methylation levels of the *cGAS*, *MAVS*, and *TRAF3* gene promoter regions in the CPL group (CPL*~cGAS~* = 35.40%, CPL*~MAVS~* = 24.26%, and CPL*~TRAF3~* = 96.76%) were significantly higher than in the control group (Control*~cGAS~* = 31.87%, Control*~MAVS~* = 21.16%, and Control*~TRAF3~* = 96.26%; *P~cGAS~*\< 0.001, *P~MAVS~*\< 0.001, and *P~TRAF3~* = 0.001), while there were no significant differences between the CC and control groups ([**Figure 2**](#f2){ref-type="fig"}).

###### 

Promoter methylation status of cyclic GMP-AMP synthase (*cGAS)*/mitochondrial antiviral-signaling (*MAVS*)/tumor necrosis factor receptor-associated factor 3 (*TRAF3*) in control, cervical precancerous lesion (CPL), and cervical cancer (CC).

  Methylation status             Median (%)   *p* value                          
  ------------------------------ ------------ ----------- -------- ------------- -----------
  CpG site of *cGAS*                                                             
  C1                             62.09        66.29       67.38    **0.001**     **0.003**
  C2                             50.14        54.24       53.95    **0.005**     **0.012**
  C3                             24.37        30.50       19.57    **0.001**     0.238
  C4                             25.51        28.00       23.47    **0.036**     0.837
  C5                             29.87        38.37       29.00    **\<0.001**   0.904
  C6                             31.98        40.17       31.58    **0.002**     0.523
  C7                             32.33        38.65       29.81    **\<0.001**   0.673
  C8                             19.11        26.24       17.29    **\<0.001**   0.554
  C9                             8.57         9.00        6.18     0.477         0.056
  Methylation level of *cGAS*    31.87        35.40       29.75    **\<0.001**   0.925
  CpG site of *MAVS*                                                             
  M1                             12.46        15.46       12.67    **0.005**     0.808
  M2                             5.70         7.93        7.26     **0.003**     0.121
  M3                             8.41         10.34       10.79    **0.019**     0.165
  M4                             5.09         6.93        6.79     **0.002**     **0.026**
  M5                             23.87        28.07       24.69    **0.003**     0.415
  M6                             54.19        56.70       55.07    **0.005**     0.313
  M7                             51.73        53.62       53.01    **0.005**     0.242
  M8                             24.32        26.92       23.30    **0.042**     0.433
  M9                             12.25        16.12       14.24    **0.007**     0.462
  M10                            6.58         6.98        9.53     0.160         **0.032**
  Methylation level of *MAVS*    21.16        24.26       22.12    **\<0.001**   0.236
  CpG site of *TRAF3*                                                            
  T1                             95.48        95.96       95.71    **0.013**     0.606
  T2                             98.12        100.00      100.00   **0.021**     0.079
  T3                             97.21        100.00      100.00   **0.006**     **0.006**
  T4                             97.11        97.98       96.73    **0.019**     0.206
  T5                             93.03        93.65       92.76    0.227         **0.047**
  Methylation level of *TRAF3*   96.26        96.76       96.65    **0.001**     0.324

Statistically significant p values (p \< 0.05) in bold font were based on the Mann-Whitney U test.

![Comparison of gene promoter methylation levels. **(A)** Cyclic GMP-AMP synthase (*cGAS*), **(B)** mitochondrial antiviral-signaling (*MAVS*), **(C)** tumor necrosis factor receptor-associated factor 3 (*TRAF3*). The reference is control group, and differences between pairs were assessed using Mann-Whitney U test. Scatter dot plot represents the methylation level and the line in plot present the median with interquartile range.](fgene-10-01123-g002){#f2}

Association of the Gene Promoter Methylation Status With the Risk of CPL and CC {#s3_3}
-------------------------------------------------------------------------------

We investigated the relationship between the gene promoter methylation status of *cGAS*, *MAVS*, and *TRAF3* and the diseases of CPL and CC. The methylation levels in both *cGAS* and *MAVS* were associated with CPL after adjusting for age and number of pregnancies, but no associations were observed between the methylation levels and CC group ([**Table 3**](#T3){ref-type="table"}). Compared with the individuals whose methylation levels in *cGAS* were less than or equal to 31.87%, the other individuals had an increased risk of CPL by 2.49 times (OR^a^ = 2.49, 95% CI = 1.31--4.75, *P*^a^ = 0.006). Moreover, individuals with *MAVS* methylation levels above 21.16% had a 1.97 times higher risk of CPL than the others (OR^a^ = 1.97, 95% CI = 1.06--3.69, *P*^a^ = 0.033). After adjusting for age and number of pregnancies, C1, C2, C3, C5, C6, C7, and C8 of *cGAS*, M2, M3, M5, M6, M7, and M9 of *MAVS* and T2, T3, T4, and T5 of *TRAF3* were associated with CPL, and C1, C2, C8, and C9 of *cGAS* were associated with the CC group ([**Table S2**](#SM1){ref-type="supplementary-material"}).

###### 

Association analysis of the promoter methylation level of cyclic GMP-AMP synthase (*cGAS*)/mitochondrial antiviral-signaling (*MAVS*)/tumor necrosis factor receptor-associated factor 3 (*TRAF3*) gene with the risk on cervical precancerous lesion (CPL), and cervical cancer (CC).

  Group     Methylation level   OR (95% CI)   *P*                 OR^a^ (95% CI)   *P*^a^              
  --------- ------------------- ------------- ------------------- ---------------- ------------------- -----------
  *cGAS*                                                                                               
  Control   49 (50.52)          48 (49.48)    1.00                                 1.00                
  CPL       23 (30.67)          52 (69.33)    2.31 (1.23--4.34)   **0.009**        2.49 (1.31--4.75)   **0.006**
  CC        18 (54.55)          15 (45.45)    0.85 (0.39--1.88)   0.689            0.91 (0.38--2.19)   0.832
  *MAVS*                                                                                               
  Control   49 (50.52)          48 (49.48)                                                             **\`**
  CPL       26 (34.67)          49 (65.33)    1.92 (1.04--3.58)   **0.039**        1.97 (1.06--3.69)   **0.033**
  CC        13 (39.39)          20 (60.61)    1.57 (0.70--3.51)   0.271            1.48 (0.62--3.52)   0.380
  *TRAF3*                                                                                              
  Control   49 (50.52)          48 (49.48)                                                             
  CPL       31 (41.33)          44 (58.67)    1.45 (0.79--2.66)   0.232            1.45 (0.79--2.66)   0.237
  CC        13 (39.39)          20 (60.61)    1.57 (0.70--3.51)   0.271            2.21 (0.90--5.43)   0.083

Low, cGAS ≦ 31.87%, MAVS ≦ 21.16%, TRAF3 ≦ 96.26%; High, cGAS \> 31.87%, MAVS \> 21.16%, TRAF3 \> 96.26%. Statistically significant p values (p \< 0.05) in bold font was based on logistic regression. ^a^Adjusted odds ratio (OR) on age and number of pregnancies.

Association between the Biological Interaction and the Diseases of CPL and CC {#s3_4}
-----------------------------------------------------------------------------

There were no relationships between hrHPV and gene promoter methylation levels in the different groups ([**Table S3**](#SM1){ref-type="supplementary-material"}); therefore, we further explored the biological interactions of hrHPV and methylation levels and the estimated risk of CPL and CC. A synergistic interaction was found between the presence of hrHPV and the gene promoter methylation levels in *cGAS* as well as in *MAVS* in CPL (AP^a^*~cGAS~* = 0.54, 95% CI = 0.13--0.95; AP^a^*~MAVS~* = 0.50, 95% CI = 0.01--0.99), and no potential interactions were observed in CC ([**Table S4**](#SM1){ref-type="supplementary-material"}).

The interactions of the presence of hrHPV and methylation levels of *cGAS* and *MAVS* were associated with an increased risk of CPL ([**Tables S5**](#SM1){ref-type="supplementary-material"} and [**S6**](#SM1){ref-type="supplementary-material"}). As shown in [**Figure 3A**](#f3){ref-type="fig"}, the individuals with hrHPV infection and *cGAS* methylation levels above 31.87% might increase the 7.70-fold risk of CPL compared with the others, who had *cGAS* methylation levels lower than or equal to 31.87% and were hrHPV-negative (OR^a^ = 7.70, 95% CI = 2.84-20.88, *P*^a^ \< 0.001). Moreover, compared with the individuals who had *MAVS* methylation levels less than or equal to 21.16% without hrHPV infection, the risk of CPL was 4.33-fold higher in those who were hrHPV-positive and had *MAVS* methylation levels above 21.16% (OR^a=^ 4.33, 95% CI = 1.78-10.52, *P*^a^ = 0.001) ([**Figure 3B**](#f3){ref-type="fig"}).

![Risk analysis of the two-factor interaction of high-risk human papillomavirus (hrHPV) and promoter methylation levels in the cervical precancerous lesion (CPL). **(A)** The interaction between hrHPV and methylation level of cyclic GMP-AMP synthase (*cGAS*). The reference group is the combination of hrHPV-negative (including lrHPV-positive and HPV negative individuals) and *cGAS* methylation levels ≦ 31.87%. \**P* 0.001, adjusted odds ratio (OR) on age and number of pregnancies. **(B)** The interaction between hrHPV and methylation level of mitochondrial antiviral-signaling (*MAVS*). The reference group is the combination of hrHPV-negative (including lrHPV-positive and HPV negative individuals) and *MAVS* methylation levels ≦ 21.16%. \**P* = 0.001, adjusted OR on age and number of pregnancies.](fgene-10-01123-g003){#f3}

The MDR analysis was used to test the interaction among gene promoter methylation levels, hrHPV infection and some other variables; however, multifactor interaction models were not found in CPL or CC ([**Table S7**](#SM1){ref-type="supplementary-material"}).

Discussion {#s4}
==========

This is the first study that describes the roles of DNA methylation in the promoter regions of the important innate immune pathways of *cGAS*, *MAVS*, and *TRAF3* in CPL and CC. The methylation levels in the promoter regions of *cGAS*, *MAVS*, and *TRAF3* were significantly increased in the CPL group compared with the healthy control group, while there were no statistically significant differences between the control and CC groups, suggesting that aberrant DNA methylation in the gene promoter regions of *cGAS*, *MAVS*, and *TRAF3* are the early events in the progression of cervical neoplasm.

The carcinogenesis of cervix exhibits the dynamics of DNA methylation changes ([@B57]; [@B63]; [@B60]), which remains largely unexplored. DNA methylation alterations across the numerous genes are seen even in early carcinogenesis. The cervical cancer model showed that gain of abnormal methylation at some genes in stem cells can be detected up to 3 years in advance of the appearance of precancerous cells, while this process of methylation status was changing during cancer progression ([@B63]). The methylation status might be affected by different factors from the stages of SIL to invasive cancer because the progression may result from the accumulation of genetic and epigenetic alterations with various environmental risks over a long period of time ([@B2]; [@B48]; [@B53]). Increasing evidence has shown that epigenetic changes as a result of aberrant hypermethylation of CpG islands in promoters or histone modifications are essential to carcinogenesis and metastasis ([@B47]). Our study systematically analyzed the promoter methylation status of *cGAS*, *MAVS*, and *TRAF3* genes, which can be identified as new promising methylation markers for the detection of cervical precancerous disease in the early stages.

The patient age and number of pregnancies were significantly higher in the CC group than in the control group, and no significant differences were observed between the CPL and control groups, which was consistent with the results from a study by Castle et al. that showed multiple pregnancies had little or no impact on the development of CPL ([@B8]). The association between the number of pregnancies and CC risk was also identified in Muñoz's study ([@B38]). Some studies revealed that older age was a risk factor for CPL and CC diseases ([@B39]; [@B54]). The women over 40 years old were at greater risk for invasive CC than those less than 40 years old, and this result could account for the longer period for potential exposure to the HPV virus and the time required for precancerous lesions to develop into invasive cancer ([@B39]). In our study, age was significantly higher only in the CC group than in the control group; this result was similar to that in the Gessesse et al. study, which documented the absence of statistically significant age in CPL ([@B17]).

We found that the elevated methylation levels in *cGAS* and *MAVS* promoter regions were risk factors for cervical precancerous disease after adjusting for age and number of pregnancies. The *cGAS*/*STING* and *RIG-I*/*MAVS* pathways were closely related to HPV infection and to CPL and CC ([@B26], [@B61], [@B19]), but the mechanisms are still unclear. In our study, the promoter methylation levels of *cGAS* and *MAVS* were elevated, which may affect the function of innate immunity of the *cGAS*/*STING* and *RIG-I*/*MAVS* pathways in the development of CPL. The innate immune responses are acute and temporary in the early stage, and it takes many years or even decades to advance from precancer to invasive cancer in the cervix during persistent HPV infection in women ([@B58]). Thus, the methylation levels of *cGAS* and *MAVS* might gradually become stable during the long progression of CC, with little or no impact on this stage. Abnormal methylation levels of many genes, such as tumor suppressor genes and DNA repair genes, are closely related to CPL and CC diseases ([@B11]; [@B15]; [@B20]; [@B23]; [@B35]; [@B28]), and several studies demonstrated that methylation analysis is a potential diagnostic tool for cervical precancerous or cancer screening that may potentially be used alone or in conjunction with cytology and/or HPV([@B15], [@B35]). Moreover, a study by Bierkens indicated that methylation analysis was capable of accurately detecting HSIL that was missed by cytology, which potentially resulted from the absence of intact indicator cells or cytological sampling errors ([@B5]). Therefore, the aberrant methylation levels of the *cGAS* and *MAVS* gene promoters may be an early event in carcinogenesis and could act as potential markers for screening CPL at early stages.

Markedly, we found two synergistic interactions in CPL, which were hrHPV infection with *cGAS* methylation levels and hrHPV infection with *MAVS* methylation levels. DNA methyltransferases (DNMTs) are mammalian enzymes responsible for maintaining CpG methylation, and DNMT1 can be activated by both E6 and E7 of hrHPV ([@B55]). E6 can upregulate DNMT1 *via* p53, and E7 can directly bind to and activate DNMT1 ([@B7]; [@B4]). Conversely, silencing of E6 and E7 could reduce DNA methylation levels and restore the transformed phenotype in CC cells ([@B45]; [@B31]; [@B55]). We hypothesize that DNMT1 is activated by hrHPV that methylation levels in the *cGAS* and *MAVS* promoter regions are elevated, and that there are synergistic interactions between the increased *cGAS* and *MAVS* methylation levels and hrHPV. Thus, women with hrHPV infection and higher promoter methylation levels in the *cGAS* and *MAVS* promoter region might have a higher probability of developing CPL than the others who have lower methylation levels and are hrHPV-negative. In the MDR analysis, we did not identify any gene-gene or gene-environment interaction in CPL or CC, but we cannot rule out the possibility of multiple interactions that have no roles in these diseases. This result may be due to the few environmental factors included in our analysis, so we should collect more demographic data in future research studies.

There are some limitations in our study. First, the sample size was not large enough, among which the number of cases in the CC group was small; this limitation may give rise to the increase in statistical error about probability of category II, leading to test power decrease and being prone to false-negative results. Therefore, more samples need to be collected for subsequent studies to validate our research. Additionally, the case-control study design may affect the accuracy of the methylation analysis results because of the detection delay times; therefore, we should carry a prospective observational study to dynamically monitor methylation levels at different time points and stages in future studies.

In conclusion, the methylation levels in the promoter regions of *cGAS*, *MAVS*, and *TRAF3* are higher in the CPL group than in the CC and control group, indicating that hypermethylation in the innate immunity pathway may be an early event in the progression of CIN. The methylation levels in the promoter regions of *cGAS* and *MAVS* are related to CPL; moreover, the respective interactions of hrHPV infection with *cGAS* or *MAVS* methylation levels may have roles in CPL. Our study provides a new epidemiological clue about the role of biomarker screening and the clinical prevention of CPL and CC.
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